UEGW 2018

Murakami T, Tokyo, OP205 Limitations of endoscopic resection for colorectal submucosal invasive carcinoma arising in sessile serrated adenoma/polyp.

PEREZ K – Paris A COMPREHENSIVE MOLECULAR CLASSIFICATION OF CROHN’S DISEASE USING GENE EXPRESSION DATA

Goh M.J, Paik N, Sinn D.H, Kang W, Gwak G.-Y, Paik Y.-H, Choi M.S, Lee J.H, Koh K.C, Paik S.W. Corée du Sud. STATIN USE ANS THE RISK OF HEPATOCELLULAR CARCINOMA IN PATIENTS WITH CHRONIC HEPATITIS B.

Franco L.M, Rodriguez M, Navascues C.A, Antón S, Ferrusquía J, Ríos A, Fraile M, Gonzalez-Dieguez L, Valle C, Varela M, De la Vega J, Graviss E, Nguyen D, Victor D.W. Espagne. RISK SCORE MODEL TO PREDICT EARLY READMISSION IN DECOMPENSATED CIRRHOSIS.

ROBLIN X. – France / INTEREST IN THE ADDITION OF AZATHIOPRINE (AZA) TO THE SWITCH OF ANTI-TNF IN IBD PATIENTS IN CLINICAL RELAPSE WITH UNDETECTABLE ANTI-TNF TROUGH LEVELS AND ANTI-DRUG ANTIBODIES: A PROSPECTIVE RANDOMIZED TRIAL.

Barner-Rasmussen N, Färkkila M.A. Finlande. SURVIVAL OF PRIMARY CHOLANGITIS : A POPULATION-BASED STUDY IN FINLAND.

Britt ten Böhmer B, Haal S, Balkema S, Depla A.C.T.M, Fockens P, Van Hooft J.E, Jansen J.M, Kuiken S.D, Liberov B.I, van Soest E, Voermans R.P. Pays-Bas. INFLUENCE OF ANTIBIOTIC DURATION IN CHOLANGITIS AFTER SUCCESSFUL DRAINAGE BY ERCP.

Casanova MJ – Madrid – EFFICACY AND SAFETY OF THE SEQUENTIAL USE OF A SECOND AND THIRD ANTI-TNF DRUG IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Woo Hyun Paik, Séoul, Corée du Sud, EuS-Guided Biliary drainage Versus ErcP for the Primary Palliation of Malignant Biliary obstruction: A Multicenter randomized clinical trial

Sands Bruce E. – USA / SAFETY AND EFFICACY OF USTEKINUMAB INDUCTION THERAPY IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 UNIFI STUDY

Toer W. Stevens, University of Amsterdam, Amsterdam., PO326 Faecal calprotectin discriminates cryptoglandular from Crohn’s disease perianal fistulas

K. Yamashita, Japan

Mohamed B, Emara Elzanan M.H, Elshamy M, Tai C. Royaume-Uni/Egypte. PERCUTANEOUS INJECTION OF ETHANOL AND MITOXANTRONE VERSUS RADIOFREQUENCY ABLATION IN THE TREATMENT OH HEPATOCELLULAR CARCINOMA.

Herrera-deGuise C.1, Varela E.1, Robles V.1, Casellas F.1, Borruel Sainz N.1, Guarner Aguilar F.1 1Unitat Atenció Crohn-Colitis (UACC), Hospital Universitari Vall d’Hebron, Barcelona, Spain., OP333 – ULCERATIVE COLITIS PATIENTS IN LONG-TERM STABLE REMISSION RECOVER EUBIOTIC CHARACTERISTICS OF THEIR MICROBIOTA

Rainer F, Medical University of Graz, Graz, Austria., OP179 – FROZEN DONOR STOOL FOR FECAL MICROBIOTA TRANSPLANTATION IS AS EFFECTIVE AS FRESH STOOL IN INDUCING RESPONSE AND REMISSION IN ACTIVE ULCERATIVE COLITIS.

Ianiro G.1, Masucci L.2, Quaranta G.2, Simonelli C.1, Lopetuso L.R.1, Napoli M.1, Sanguinetti M.2, Gasbarrini A.1, Cammarota G.1 1IRCCS Fondazione Agostino Gemelli University Hospital, Digestive Disease Center, Rome, Italy, 2IRCCS Fondazione Agostino Gemelli University Hospital, Microbiology Institute, Rome, ItalyOP181 – RANDOMISED CLINICAL TRIAL: SINGLE INFUSION- VERSUS MULTIPLE INFUSION-FAECAL MICROBIOTA TRANSPLANTATION FOR THE TREATMENT OF SEVERE CLOSTRIDIUM DIFFICILE INFECTION REFRACTORY TO ANTIBIOTICS

Halkjær S.I.1, Christensen A.H.2, Lo B.Z.S.1, Browne P.3, Günther S.2, Hansen L.H.3, Petersen A.M.1 1Copenhagen University Hospital Hvidovre, Department of Gastroenterology, Hvidovre, Denmark, 2Aleris-Hamlet Hospitaler, Søborg, Denmark, 3Aarhus University, Department of Environmental Science, Roskilde, Denmark, OP035 – FECAL MICROBIOTA TRANSPLANTATION ALTERS GUT MICROBIOTA IN PATIENTS WITH IRRITABLE BOWEL SYNDROME: RESULTS FROM A RANDOMIZED, DOUBLE-BLIND PLACEBO CONTROLLED STUDY

Graham D – Houston / USA PHASE III RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ADD-ON FIXED-DOSE ANTI-MYCOBACTERIAL THERAPY (RHB-104) IN MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE (MAP US)

Sandborn WJ – USA / EFFICACITY AND SAFETY OF USTEKINUMAB FOR CROHN’S DISEASE: RESULTS FROM IMUNITI LONG-TERM EXTENSION THROUGH 3 YEARS

Burisch J. – Frederikssund Danmark IS THERE A COST-SAVING EFFECT OF BIOLOGICAL THERAPY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE? RESULTS FROM A PROSPECTIVE EUROPEAN POPULATION-BASED INCEPTION COHORT

E. Waldmann, Austria

OP 291 THE OLD VERSUS THE NEW: WHAT IS DIFFERENT IN COLORECTAL CANCER ?, Syed A. United States

Barnhoorn M.1, Molendijk I.1, Bonsing B.A.2, Roelofs H.3, Maljaars J.P.W.1, Peeters K.2, Wasser M.N.J.M.4, Oosten L.E.M.3, Dijkstra G.5, van der Woude C.J.6, Duijvestein M.7, Veenendaal R.A.1, Zwaginga J.3, Verspaget H.W.1, Fibbe W.E.3, Hommes D.W.1,8, Van der Meulen – De Jong A.1 1Leiden University Medical Center, Gastroenterology and Hepatology, Leiden, Netherlands, 2Leiden University Medical Center, Surgery, Leiden, Netherlands, 3Leiden University Medical Center, Immunohematology and Blood Transfusion, Leiden, Netherlands, 4Leiden University Medical Center, Radiology, Leiden, Netherlands, 5UMC Groningen, Gastroenterology and Hepatology, Groningen, Netherlands, 6Erasmus Medical Center, Gastroenterology, Rotterdam, Netherlands, 7AMC, Gastroenterology and Hepatology, Amsterdam, Netherlands, 8University of California Los Angeles, Digestive Diseases, Los Angeles, United States, OP060 – LONG-TERM EFFICACY AND SAFETY OF ALLOGENEIC BONE MARROW-DERIVED MESENCHYMAL STROMAL CELLS FOR PERIANAL FISTULAS IN PATIENTS WITH CROHN’S DISEASE: A 4-YEAR FOLLOW-UP STUDY